{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=monoclonal+antibody+CD20&page=7", "query": { "intervention": "monoclonal antibody CD20", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 426, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=monoclonal+antibody+CD20&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=monoclonal+antibody+CD20&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:43:08.908Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00477412", "title": "Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 107, "start_date": "2007-04-03", "completion_date": "2020-10-28", "has_results": true, "last_update_posted_date": "2022-01-28", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477412" }, { "nct_id": "NCT00006708", "title": "S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2000-10", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 85, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006708" }, { "nct_id": "NCT02135874", "title": "Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Leukemia of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Mixed Phenotype Acute Leukemia", "Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified", "Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified", "Recurrent Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-10-27", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02135874" }, { "nct_id": "NCT01035463", "title": "Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Negative", "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 74, "start_date": "2009-11-12", "completion_date": "2018-07-27", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 3, "location_summary": "Westwood, Kansas • Omaha, Nebraska • Cleveland, Ohio", "locations": [ { "city": "Westwood", "state": "Kansas" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01035463" }, { "nct_id": "NCT06119685", "title": "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NHL", "Multiple Myeloma", "Blood Cancer", "Refractory Non-Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "IDP-023", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indapta Therapeutics, INC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2023-10-25", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 12, "location_summary": "Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119685" }, { "nct_id": "NCT05065554", "title": "ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgM MGUS", "Waldenstrom Macroglobulinemia", "Neuropathy;Peripheral" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shayna Sarosiek, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-11-16", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05065554" }, { "nct_id": "NCT06186219", "title": "Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tophaceous Gout" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2024-04-10", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186219" }, { "nct_id": "NCT01886872", "title": "Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 547, "start_date": "2014-01-15", "completion_date": "2027-06-24", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 917, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01886872" }, { "nct_id": "NCT04872790", "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Mixed Phenotype Acute Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-02", "completion_date": "2027-12-02", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872790" }, { "nct_id": "NCT07578077", "title": "Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Golcadomide", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2026-12-21", "completion_date": "2030-04-21", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-14T04:43:08.908Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07578077" } ] }